Goldman Sachs Group Inc. Sells 501,725 Shares of Sanofi $SNY

Goldman Sachs Group Inc. trimmed its stake in Sanofi (NASDAQ:SNY) by 20.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,977,603 shares of the company’s stock after selling 501,725 shares during the quarter. Goldman Sachs Group Inc.’s holdings in Sanofi were worth $95,835,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of the stock. Advisory Services Network LLC grew its holdings in Sanofi by 1.4% in the third quarter. Advisory Services Network LLC now owns 15,733 shares of the company’s stock worth $743,000 after purchasing an additional 210 shares during the period. Savant Capital LLC grew its holdings in Sanofi by 2.7% in the fourth quarter. Savant Capital LLC now owns 8,623 shares of the company’s stock worth $418,000 after purchasing an additional 225 shares during the period. Wesbanco Bank Inc. grew its holdings in Sanofi by 4.9% in the fourth quarter. Wesbanco Bank Inc. now owns 4,927 shares of the company’s stock worth $239,000 after purchasing an additional 230 shares during the period. IFG Advisory LLC grew its holdings in Sanofi by 2.7% in the fourth quarter. IFG Advisory LLC now owns 9,213 shares of the company’s stock worth $446,000 after purchasing an additional 244 shares during the period. Finally, GAMMA Investing LLC raised its position in shares of Sanofi by 5.5% during the fourth quarter. GAMMA Investing LLC now owns 5,058 shares of the company’s stock worth $245,000 after purchasing an additional 264 shares during the period. 14.03% of the stock is currently owned by institutional investors and hedge funds.

Sanofi Stock Up 1.9%

Sanofi stock opened at $44.73 on Wednesday. Sanofi has a fifty-two week low of $42.28 and a fifty-two week high of $52.68. The stock has a market cap of $108.44 billion, a PE ratio of 12.49, a price-to-earnings-growth ratio of 1.08 and a beta of 0.34. The firm’s 50-day simple moving average is $45.36 and its 200 day simple moving average is $46.64. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.22 and a current ratio of 1.01.

Sanofi Increases Dividend

The business also recently disclosed an annual dividend, which was paid on Wednesday, June 3rd. Shareholders of record on Monday, May 4th were given a $2.4225 dividend. This is a positive change from Sanofi’s previous annual dividend of $2.04. This represents a yield of 559.0%. The ex-dividend date of this dividend was Monday, May 4th. Sanofi’s payout ratio is presently 49.16%.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the company. Argus raised Sanofi to a “strong-buy” rating in a research report on Monday, April 27th. Sanford C. Bernstein upgraded shares of Sanofi to a “strong-buy” rating in a report on Thursday, March 19th. Wall Street Zen cut shares of Sanofi from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 21st. BNP Paribas Exane cut shares of Sanofi from an “outperform” rating to a “neutral” rating and set a $50.00 price objective for the company. in a report on Monday, April 20th. Finally, Morgan Stanley set a $52.00 price objective on shares of Sanofi in a report on Friday, May 1st. Two analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and ten have given a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $51.00.

Sanofi Company Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.